Entera is on the Cusp of the Trial That Could Unlock America's Osteoporosis Drug Market (NASDAQ: ENTX)businessinsider·Aug 31 at 01:15 PMENTX+3.25%
Correction: Entera to Participate in Upcoming Fall Investor ConferencesUnusual Whales·Aug 27 at 01:45 PMENTX+3.25%
Entera Bio CEO Toledano joins Cantor Global Healthcare Conference fireside chatPUBT·Aug 27 at 12:04 PMENTX+3.25%
Entera Bio files Form 3 for Chief Medical Officer Riccardo Paolo CamisascaPUBT·Aug 21 at 11:35 AMENTX+3.25%
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA AgreementMarket Beat·Aug 13 at 06:04 PMENTX+3.25%
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%Market Beat·Aug 13 at 10:40 AMENTX+3.25%
Entera Announces Second Quarter 2026 Financial Results and Business UpdatesUnusual Whales·Aug 7 at 08:10 PMENTX+3.25%
Entera Bio Q2 FY26 net loss widens to $7.3 million; R&D expenses more than double to $3.2 millionPUBT·Aug 7 at 08:05 PMENTX+3.25%
